Search results for: “REGN”
-
Regeneron Pharmaceuticals Inc Valuation – February 2019 $REGN
Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.
-
Regeneron Pharmaceuticals Inc Valuation – April 2018 $REGN
Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.
-
Regeneron Pharmaceuticals Inc Valuation – November 2016 $REGN
Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.
-
Regeneron Pharmaceuticals Inc Valuation – August 2016 $REGN
Regeneron Pharmaceuticals Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the insufficient earnings stability or growth over the last ten years, and the poor dividend history, and the high PEmg and PB ratios.
-
Regeneron Pharmaceuticals Inc. Annual Valuation – 2015 $REGN
Regeneron Pharmaceuticals is not suitable for either the Defensive Investor or the Enterprising Investor. The Defensive Investor is concerned with the lack of dividends, insufficient earnings growth or stability over the last ten years along with the high PEmg and PB ratios.
-
Regeneron Pharmaceuticals Inc. (REGN) Annual Valuation – 2014
Regeneron Pharmaceuticals is not suitable for either the Defensive Investor or the Enterprising Investor. For the Defensive Investor, the company has shown insufficient earnings stability or growth over the ten year historical period, does not pay dividends, and is trading at a high PEmg ratio.
-
Johnson & Johnson Valuation – April 2019 #JNJ
Johnson & Johnson does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings growth over the last ten years, and the high PEmg and PB ratios.
-
Bristol-Myers Squibb Co Valuation – April 2019 #BMY
Bristol-Myers Squibb Co is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, high PB ratio.
-
Biogen Inc Valuation – March 2019 #BIIB
Biogen Inc qualifies for both the Defensive Investor and the Enterprising Investor. The Defensive Investor is only initially concerned with the poor dividend history.
-
Mylan NV Valuation – March 2019 #MYL
Mylan NV does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, poor dividend history.